Company
GeneCentric
a company making precision medicine more precise by bringing gene expression biology to liquid biopsy
- Business model
- B2B
- Customers
- biopharma and diagnostics companies and commercial labs
- Legal name
- GeneCentric Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
GeneCentric’s mission is to address the urgent unmet need in precision oncology for better biomarkers and to bring these biomarkers to liquid biopsies.
Funding snapshot
- Total raised
- $21.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $2M2025-06-04
Funding rounds
- Round, 2025
- $2M2025-06-04, SEC form D sold, 9 investors
- Round, 2022
- $2.5M2022-09-08, SEC form D sold, 1 investor
- Round, 2021
- $4.5M2021-09-22, SEC form D sold, 1 investor
- Round, 2020
- $1.2M2020-12-29, SEC form D sold, 4 investors
- Round, 2016
- $6.1M2016-12-22, SEC form D sold, 4 investors
- Round, 2013
- $5M2013-06-19, SEC form D sold, 4 investors
- Round, 2011
- $250K2011-09-02, SEC form D sold, 2 investors
Products
- Web
- ExpressCT
- Web
- ExpressCT Rewind
- Web
- GenomicsNext
- Web
- PurIST
Loading relationship preview